Author: Yechezkel, Itai; Law, Mansun; Tzarum, Netanel
Title: From Structural Studies to HCV Vaccine Design Cord-id: s8ypa5ez Document date: 2021_5_4
ID: s8ypa5ez
Snippet: Hepatitis C virus (HCV) is a serious and growing public health problem despite recent developments of antiviral therapeutics. To achieve global elimination of HCV, an effective cross-genotype vaccine is needed. The failure of previous vaccination trials to elicit an effective cross-reactive immune response demands better vaccine antigens to induce a potent cross-neutralizing response to improve vaccine efficacy. HCV E1 and E2 envelope (Env) glycoproteins are the main targets for neutralizing ant
Document: Hepatitis C virus (HCV) is a serious and growing public health problem despite recent developments of antiviral therapeutics. To achieve global elimination of HCV, an effective cross-genotype vaccine is needed. The failure of previous vaccination trials to elicit an effective cross-reactive immune response demands better vaccine antigens to induce a potent cross-neutralizing response to improve vaccine efficacy. HCV E1 and E2 envelope (Env) glycoproteins are the main targets for neutralizing antibodies (nAbs), which aid in HCV clearance and protection. Therefore, a molecular-level understanding of the nAb responses against HCV is imperative for the rational design of cross-genotype vaccine antigens. Here we summarize the recent advances in structural studies of HCV Env and Env-nAb complexes and how they improve our understanding of immune recognition of HCV. We review the structural data defining HCV neutralization epitopes and conformational plasticity of the Env proteins, and the knowledge applicable to rational vaccine design.
Search related documents:
Co phrase search for related documents- acute hcv infection and liver cirrhosis: 1, 2
- acute hcv infection and liver disease: 1, 2
- acute sars respiratory syndrome coronavirus and additional structure: 1, 2, 3, 4
- acute sars respiratory syndrome coronavirus and liver cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute sars respiratory syndrome coronavirus and liver cirrhosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute sars respiratory syndrome coronavirus and liver damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars respiratory syndrome coronavirus and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars respiratory syndrome coronavirus and low density: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute sars respiratory syndrome coronavirus and low density lipoprotein receptor: 1
- acute viremia and liver damage: 1
- acute viremia and liver disease: 1
- liver cancer and low density: 1, 2, 3
- liver cirrhosis and low density: 1
- liver cirrhosis and low density lipoprotein receptor: 1
- liver damage and low density: 1, 2
- liver disease and low density: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Co phrase search for related documents, hyperlinks ordered by date